|
Human sCD26 ELISA Kit
Description:
Human sCD26 ELISA Kit
Trade Name:
Chemicon (Millipore)
Qty/Pk:
1 kit
Product Overview:
CD26, a T cell activation antigen, is a 110kDa cell surface glycoprotein with known dipeptidyl peptidase IV (DPPIV (Morimoto, C. et al., 1989); EC 3.4.14.5) activity in its extracellular domain, which is present on various cell types, including T cells and epithelial cells of the liver, kidney, and intestine (Hegen et al., 1990; Morimoto & Schlossman, 1994; Ulmer et al., 1990). Of the T cell antigens described to date, CD26 has proved to be one of the most intriguing in the scope of its functional associations. Considerable evidence suggests that CD26 can deliver a potent costimulatory signal to T-cells (Fleischer, 1987). This signal transducing property appears to be a property of its extracellular domain (Duke-Cohan et al., 1996). In addition, CD26 appears to be a functional collagen receptor (Dang et al., 1990) that may aid activated T-cells in localizing to inflammatory regions (Masuyama et al., 1992). It has also been demonstrated that CD26 not only acts as a functional dipeptidyl peptidase IV, but also binds strongly to adenosine deaminase (Dong et al., 1996).
Significant levels of DPPIV activity have been shown to exist in plasma, serum, and urine (Chikuma et al., 1990; Maes et al., 1994; Scharpe et al., 1988). The serum form of DPPIV is unique, with a high molecular weight of 175kDa, and is not a breakdown product of membrane CD26 (105-110kDa), nevertheless exposing significant structural similarity to the membrane form (Duke-Cohan et al., 1995, 1996).
Like many other T-cell molecules, CD26 is associated with HIV disease progression. There is a correlation of CD26 expression and HIV entry, replication and cytopathicity (Oravecz et al., 1995). CD26 has been identified as a key marker for monocytotropic HIV-1 infection, with a mechanism of early loss of CD26 - expressing cells in HIV-1 infected individuals described.
CD26 as an indicator of T-cell activation has been shown to fluctuate in parallel with several autoimmune diseases such as rheumatoid arthritis (Nakao et al., 1989) and autoimmune thyroiditis (Eguchi et al., 1989). CD26 has been described as a marker that correlates well with the level of activity of these diseases. It has furthermore been studied as an indicator of disease progression in chronic progressive multiple sclerosis (Constantinescu et al., 1995).
Test Principles:
An anti-sCD26 monoclonal coating antibody is adsorbed onto microwells.
Soluble CD26 (sCD26) present in the sample or standard binds to antibodies adsorbed to the microwells; a biotin?conjugated monoclonal anti-sCD26 antibody is added and binds to sCD26 captured by the first antibody.
Following incubation unbound biotin conjugated anti-sCD26 is removed during a wash step. Streptavidin-HRP is added and binds to the biotin-conjugated anti-sCD26. Following incubation unbound Streptavidin-HRP is removed during a wash step, and substrate solution reactive with HRP is added to the wells.
A colored product is formed in proportion to the amount of sCD26 present in the sample. The reaction is terminated by addition of acid and absorbance is measured at 450nm. A standard curve is prepared from six sCD26 standard dilutions and sCD26 sample concentration determined.
Application:
The sCD26 ELISA is an enzyme-linked immunosorbent assay for quantitative detection of soluble human CD26 in cell culture supernatants, human serum, plasma or other body fluids. The sCD26 ELISA is for research use only. Not for use in diagnostic or therapeutic procedures.
View All »
Applications:
The sCD26 ELISA is an enzyme-linked immunosorbent assay for quantitative detection of soluble human CD26 in cell culture supernatants, human serum, plasma or other body fluids.
Key Applicatio |